Rabeprazole sodium enteric-coated tablets were approved, A new member of the Qingfeng digestive family

On August 3, the NMPA approved the marketing of Rabeprazole Sodium Enteric-coated Tablets developed by Shanxiang Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group. This is the second proton pump inhibitor approved by Qingfeng Pharmaceutical Group in the field of digestion.

Rabeprazole sodium enteric-coated tablets are second-generation proton pump inhibitors and are the most active proton pump inhibitors against Helicobacter pylori. They are mainly used in the treatment of gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis and Zollinger-Ellison syndrome. They are the mainstream oral proton pump inhibitors in China.